This efficient survey and meta-investigation meant to evaluate the prognostic estimation of consecutive of abiraterone (ABI) and enzalutamide (ENZ) treatment in patients with castration-resistant prostate cancer (CRPC). Ten investigations with 1096 patients were qualified for the efficient survey and eight examinations with 643 patients for the meta-investigation. The ABI-to-ENZ arrangement was fundamentally connected with better PFS (pooled risk proportion (HR): 0.62, 95% secret span (CI): 0.49–0.78, P < 0.001), and PSA–PFS (pooled HR: 0.48, 95% CI: 0.38–0.61, P < 0.001) than the ENZ-to-ABI grouping. PSA reaction paces of the two specialists were fundamentally better with the ABI-to-ENZ succession (hazard proportion: 0.21, 95% CI: 0.09–0.47, P < 0.001). Conversely, treatment succession was not altogether connected with OS (pooled HR: 0.77, 95% CI: 0.59–1.01, P = 0.055). ABI-to-ENZ successive treatment in patients with CRPC was related with better PFS, PSA–PFS, and PSA reaction rates. Despite sequencing, reaction to sedate treatment was transient for both ABI and ENZ when either specialist was utilized as an optional treatment. In spite of this, treatment sequencing is imperative to accomplish the most extreme conceivable profit by accessible medications in CRPC.
Reference link- https://www.nature.com/articles/s41391-020-0222-6
